Column List | SMC Laboratories Inc.

2025.03.28

Exploring New Therapeutic Potential of GPCRs: A Breakthrough in GPR119-Targeted NASH/MASH Treatment

Today, we are excited to share a recent study highlighting a promising approach to targeting G protein-coupled receptors (GPCRs) in NASH/MASH treatment.This study addresses a long-standing challenge in the development of NASH/MASH therapeutics using GPCR-targeting compounds. GPR119 activation has been shown to promote GLP-1 secretion and glucose-responsive insulin secretion, making it a compelling target for…

2025.03.21

SMC’s IPF study experience

Today, we would like to introduce our experience of the bleomycin-induced IPF study. One of our most requested models, apart from our proprietary MASH model, is the bleomycin-induced IPF model for evaluations of drugs against lung fibrosis. In the past 10 years, we have conducted over 150 studies using the bleomycin-induced IPF model and…

2025.03.14

Advanced Non-Clinical COPD Model Mouse for Your Drug Development Needs

In this article, we introduce our COPD model. Why Choose Our COPD Model? ✅Clinically Relevant Evaluations: Our model includes in-life CT scans, lung function tests (FVC via flexiVent, SpO₂ by pulse oximetry), and histological analysis, closely mirroring clinical studies. ✅ Multiple Analyses from a Single Subject: We provide comprehensive assessments, including histology, gene expression,…

2025.03.07

Get the Latest CCl4 Model Material

We are pleased to share with you the latest material introducing our CCl4 model, which should provide valuable insights for your preclinical research. You can download the summary version here. (This version includes an overview and some model data) The Full version includes the following content. ・Comparison table of human and CCl4 model ・Target and modality information…

2025.02.27

Get The Latest Materials on Lung Disease Models

We are pleased to introduce the latest materials showcasing our lung disease models, designed to provide valuable insights for your pre-clinical research. You can download the digest version here: (This version includes an overview of the models and detailed information on selected models.) If you are interested in accessing the complete version (12…

2025.02.21

Get the Latest BDL Model Material

We are pleased to share with you the latest material introducing our BDL model, which should provide valuable insights for your preclinical research. You can download the summary version here. (This version includes an overview and some model data) The Full version includes the following content. ・Comparison table of human and BDL model…

2025.02.14

Get Latest UUO Model Material

We are pleased to share the latest material introducing our UUO model, which should provide valuable insights for your pre-clinical research. You can download the summary version here: (This version includes an overview and some model data) The Full version includes the following content. ・All analysis data in UUO on day 7 and 14…

2025.02.07

Pulse oximetry analysis of IPF model mice

Pulse oximetry analysis begins in IPF preclinical pharmacology study. We offer the Idiopathic Pulmonary Fibrosis (IPF) model as a potential model for the development of therapeutics for lung fibrosis, and many of our customers have used this model through our introduction of its usefulness. Our Advantages – We have started measuring SpO2 using…

2025.02.06

[CAIA research seen in an example study] Custom model service for realizing a wide range of research

In recent years, we have received many requests about our services, starting from the establishment of pathological models, in response to the increasing diversity of diseases and the needs for therapeutic drug development. Therefore, today we would like to introduce an example study regarding custom model services, for which we have received many inquiries….

2025.02.05

[Case Study] Why do disease model mice change the outcomes?

If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of your compound by using a disease induction model that is appropriate for your evaluation, rather than using a standard pathological model. In this article, we will provide a clear overview of the disease induction…